Effects of alogliptin benzoate in hemodialysis patients with diabetes

概要

論文の詳細を見る
The aim of this study was to evaluate the effects of alogliptin benzoate (alogliptin), a dipeptidase-4 inhibitor, as mono-therapy for hemodialysis (HD) patients with type2 diabetes. Among 381 HD patients, 16 diabetic HD patients (13 males and 3 females) with inadequate glycemic control (hemoglobin A1c (HbA1c) levels>6.1% and glycated albumin (GA) levels>20%) on exercise and diet were eligible to participate. No patients were taking other oral antidiabetic drugs nor receiving insulin injection therapy. The mean age was 62.5±9.2 years. Alogliptin was administered to patients at 6.25mg once a day. The following parameters were examined before and after treatment: levels of HbA1c, GA, blood glucose, insulin, C-peptide immunoreactivity, glucagon, and active glucagon like peptide-1 (GLP-1). All samples were obtained before the start of HD treatment. Significance was tested using the Wilcoxon signed-rank test for nonparametric data. HbA1c and GA levels significantly decreased in 8 weeks after the start of the administration of Alogliptin in comparison with before treatment (p<0.05). HbA1c and GA levels decreased from 6.7±0.2 to 5.6±0.2% and from 22.5±0.7 to 19.7±0.5% in 40 weeks after treatment. Among the 16 patients, 13 (81.3%) achieved HbA1c<6.1% and GA<20%. GLP-1 levels were 8.9±5.7pmol/L before treatment and these levels significantly increased by doubling after treatment (p<0.05). None of the patients exhibited significant adverse effects such as hypoglycemia, except one patient who experienced a drug rash event. Alogliptin is expected as one of the new treatment strategies for hemodialysis patients with diabetes whose choices of diabetic treatment are limited.

Effects of alogliptin benzoate in hemodialysis patients with diabetes

スポンサーリンク

概要

著者

関連論文

スポンサーリンク